Sahajanand Medical Technologies IPO is a proposed Mainboard public issue by Sahajanand Medical Technologies Limited, an Indian medical technology company specialising in cardiovascular and vascular intervention products. The company has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) in connection with its proposed initial public offering. The equity shares are intended to be listed on BSE and NSE, subject to the completion of the applicable regulatory and IPO processes.
According to the company’s DRHP, the proposed offering consists of an Offer for Sale (OFS) of equity shares by existing shareholders. The draft document describes an offer of up to 27,644,231 equity shares of face value ₹1 each. The final offer size, price band, issue dates, and other terms must be confirmed from the final offer documents and official IPO announcements.
Sahajanand Medical Technologies Limited operates in the medical devices industry, developing and supplying products used in cardiovascular and vascular interventions. Its product portfolio includes coronary stents, coronary balloons, structural heart products, and other specialised medical devices. The company serves healthcare markets in India and overseas through its manufacturing and distribution network.
Demand for advanced medical devices is influenced by the increasing prevalence of cardiovascular diseases, improvements in healthcare infrastructure, technological advancement, and greater access to specialised medical treatment. These developments may create opportunities for medical device manufacturers. However, investors should evaluate the company’s financial performance, product development capabilities, regulatory compliance, competitive position, customer concentration, and proposed IPO valuation before making an investment decision.
Table of Contents
Sahajanand Medical Technologies IPO Details
| IPO Details | Information |
|---|---|
| IPO Name | Sahajanand Medical Technologies IPO |
| Company Name | Sahajanand Medical Technologies Limited |
| IPO Type | Book Built Issue |
| IPO Category | Mainboard IPO |
| Face Value | ₹1 per equity share |
| Price Band | ₹327 to ₹344 |
| Issue Size | ₹475.48 Crore (1,38,22,116 shares) |
| Offer for Sale | ₹475.48 Crore (1,38,22,116 shares) |
| IPO Open Date | 15 October 2026 |
| IPO Close Date | 19 October 2026 |
| Anchor Investor Bidding | 14 October 2026, |
| Basis of Allotment | 21 October 2026 |
| Refund Initiation | 22 October 2026 |
| Shares Credited to Demat Account | 22 October 2026 |
| Listing Date | 23 October 2026 |
| Listing Exchange | BSE & NSE, subject to final listing approval |
| Lot Size | 43 Shares |
| Registrar | MUFG Intime India Pvt.Ltd. |
| Book Running Lead Managers | Motilal Oswal Investment Advisors Ltd |
The DRHP describes the proposed IPO as an Offer for Sale by existing shareholders. Under an OFS, the proceeds from the sale of shares go to the selling shareholders rather than to the company. The final RHP and prospectus should be checked for the confirmed number of shares offered, price band, selling shareholders, and any changes to the proposed issue structure.
Sahajanand Medical Technologies IPO Dates
The following table summarises the IPO timeline. Dates that have not been confirmed through final offer documents are left pending.
| IPO Event | Date |
|---|---|
| IPO Opening Date | 15 October 2026 |
| IPO Closing Date | 19 October 2026 |
| Basis of Allotment | 21 October 2026 |
| Refund Initiation | 22 October 2026 |
| Shares Credited to Demat Account | 22 October 2026 |
| Listing Date | 23 October 2026 |
Investors should check the final IPO schedule before submitting an application. The allotment, refund, demat credit, and listing dates depend on the final issue timetable and applicable exchange procedures.
Sahajanand Medical Technologies IPO Reservation
| Investor Category | Reservation |
|---|---|
| Qualified Institutional Buyers (QIB) | To be updated |
| Non-Institutional Investors (NII) | To be updated |
| Retail Individual Investors (RII) | To be updated |
| Employee Reservation | To be updated, if applicable |
The final allocation among investor categories must be checked in the final RHP. The applicable reservation percentages may depend on the final offer structure and any employee or other reservation portions announced by the company.
Sahajanand Medical Technologies IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 43 Shares | ₹14,792 |
| Retail Maximum | 13 | 559 Shares | ₹1,92,296 |
| S-HNI Minimum | 14 | 602 Shares | ₹2,07,088 |
| S-HNI Maximum | 67 | 2,881 Shares | ₹9,91,064 |
| B-HNI Minimum | 68 | 2,924 Shares | ₹10,05,856 |
The lot size and minimum application amount cannot be calculated accurately until the final price band and lot size are announced. Application amounts should be calculated using the final issue price applicable to the selected bid.
Grey Market Premium (GMP)
| Date | GMP | Sub2 | Kostak |
|---|---|---|---|
| 11-Oct-2026 | ₹25.00 | — | — |
| 12-Oct-2026 (Morning) | ₹40.00 | — | — |
| 12-Oct-2026 (Afternoon) | ₹45.00 | — | — |
| 12-Oct-2026 (Evening) | ₹35.00 | — | — |
| 13-Oct-2026 (Morning) | ₹40.00 | — | — |
| 13-Oct-2026 (Current) | ₹37.00 | — | — |
About Sahajanand Medical Technologies Limited
Sahajanand Medical Technologies Limited is an Indian medical technology company engaged in the development, manufacturing, and distribution of specialised medical devices. The company focuses primarily on cardiovascular and vascular intervention products used in procedures for patients requiring treatment for coronary artery disease and other vascular conditions.
The company’s portfolio includes drug-eluting stents, coronary balloons, structural heart products, occluders, renal stents, and peripheral intervention devices. Its products are designed for use by healthcare professionals in specialised medical procedures. Product development, clinical evaluation, manufacturing quality, regulatory compliance, and distribution relationships are important parts of its operating model.
Sahajanand Medical Technologies has an international presence supported by manufacturing operations in India and Thailand and business operations across overseas markets. Its products are distributed in multiple countries, giving the company exposure to a range of healthcare systems and regulatory environments. International operations can provide opportunities for growth, although they also require compliance with different product approval standards and commercial requirements.
The company has developed its position through investment in medical technology, product innovation, and specialised cardiovascular devices. Its performance depends on the adoption of its products, the ability to maintain product quality, the development of new technologies, and its capacity to compete with other medical device manufacturers.
Investors evaluating the proposed IPO should examine the company’s financial statements, product portfolio, geographic presence, customer and distributor relationships, research and development activities, and regulatory risks. The final RHP will provide the relevant financial and operational disclosures for assessing the company’s position before investing.
Business Operations
Sahajanand Medical Technologies Limited operates in the specialised medical devices industry, with a primary focus on cardiovascular and vascular intervention products.
- Vascular Intervention Products – The company develops and supplies medical devices used in vascular procedures, including coronary stents and related products.
- Drug-Eluting Stents – Its product portfolio includes drug-eluting coronary stents designed to support the treatment of narrowed coronary arteries.
- Coronary Balloon Catheters – These devices are used in interventional procedures to widen narrowed blood vessels and support coronary treatment.
- Structural Heart Products – The company participates in the structural heart segment, including transcatheter aortic valve implantation devices and other specialised products.
- Occluders – Occluder devices are used in selected procedures to close abnormal openings or defects in the heart and associated structures.
- Peripheral Intervention Products – The company’s portfolio includes products for peripheral vascular procedures, including drug-coated balloon technologies.
- Renal Stents – The company also identifies renal stents among its specialised medical device products.
- Manufacturing Operations – Manufacturing facilities in India and Thailand support its production and supply operations.
- Research and Development – Medical device innovation requires investment in product design, testing, clinical evaluation, and compliance with applicable regulatory standards.
- International Distribution – The company’s products reach markets outside India through international business operations and distribution arrangements.
The company’s business performance depends on product acceptance, regulatory approvals, manufacturing efficiency, pricing, healthcare provider relationships, and its ability to introduce and commercialise new products.
Industry Overview
The medical devices industry supports healthcare delivery through products used in diagnosis, monitoring, surgery, treatment, and specialised medical procedures. Cardiovascular medical devices form an important segment because they are used in treating heart and vascular conditions.
Demand for cardiovascular devices is influenced by the prevalence of cardiovascular disease, access to specialised hospitals, the availability of trained medical professionals, improvements in healthcare infrastructure, and adoption of advanced treatment technologies. Greater awareness of cardiovascular health and increasing access to specialised medical care may support demand for devices used in interventional procedures.
The industry also requires sustained investment in research and development, clinical evaluation, product testing, manufacturing systems, and regulatory compliance. Medical devices must meet applicable safety and quality standards in the markets where they are sold. Product approval requirements and commercial adoption can influence the speed at which new products generate revenue.
Competition from domestic and international medical device manufacturers can affect pricing, market share, and profit margins. Changes in healthcare procurement practices, regulatory requirements, product technology, and manufacturing costs can also influence industry performance.
Sahajanand Medical Technologies operates in this specialised environment. Its future prospects will depend on its product portfolio, innovation capabilities, international market access, financial performance, and ability to maintain quality and regulatory compliance.
Business Strategy
Sahajanand Medical Technologies Limited operates in specialised cardiovascular and vascular intervention devices. Its business model depends on developing relevant medical technologies, maintaining consistent manufacturing quality, and supplying products that meet the clinical and regulatory requirements of healthcare markets.
Product development and innovation are important for maintaining competitiveness in medical devices. The company’s ability to introduce new products, improve existing technologies, and obtain required regulatory approvals can influence its long-term business performance. Investment in research and development, clinical evidence, and quality systems is therefore important for its operating model.
The company also has exposure to international markets through its overseas business operations. International expansion can provide access to additional customers and healthcare markets, although it may involve regulatory complexity, currency fluctuations, distribution costs, and differing commercial conditions.
Operational efficiency, reliable supply chains, product quality, and relationships with distributors and healthcare providers are other important factors. Investors should examine the company’s stated business strategy, planned investment, research and development expenditure, and future expansion plans in the final IPO documents.
Sahajanand Medical Technologies IPO Financial Information
A company’s financial performance provides insights into revenue generation, profitability, operating efficiency, liquidity, and financial stability. Reviewing financial statements across multiple years helps investors understand changes in business scale and assess whether growth has translated into sustainable earnings.
The financial information below should be completed using the restated consolidated financial statements in the final RHP or prospectus. Figures should not be estimated from industry averages or unrelated company information.
Sahajanand Medical Technologies Financial Summary
| Particulars | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Revenue from Operations | ₹901.60 Crore | ₹1,024.88 Crore | ₹1,210.50 Crore |
| Total Income | ₹915.22 Crore | ₹1,035.96 Crore | ₹1,218.73 Crore |
| EBITDA | ₹110.05 Crore | ₹128.02 Crore | ₹170.66 Crore |
| Profit Before Tax (PBT) | -₹9.12 Crore | ₹31.40 Crore | ₹85.22 Crore |
| Profit After Tax (PAT) | -₹7.35 Crore | ₹25.15 Crore | ₹69.08 Crore |
| Net Worth | ₹540.01 Crore | ₹565.73 Crore | ₹616.05 Crore |
| Total Borrowings | ₹175.27 Crore | ₹224.96 Crore | ₹266.53 Crore |
The company’s audited and restated financial statements should be used to populate the table. Particular attention should be given to revenue growth, profitability, borrowings, working capital, and the contribution of international operations. Any subsequent financial year should be added only if the corresponding financial statements are available in the final offer documents.
Sahajanand Medical Technologies IPO Key Performance Indicators (KPIs)
Key Performance Indicators help investors evaluate profitability, operating performance, capital efficiency, and financial leverage. The following values should be taken from the final IPO documents, using the same reporting period and definitions as the issuer.
| KPI | Value |
|---|---|
| Return on Equity (ROE) | 10.35% |
| Return on Capital Employed (ROCE) | 11.57% |
| Return on Net Worth (RONW) | 10.60% |
| EBITDA Margin | 14.10% |
| PAT Margin | 5.71% |
| Debt-to-Equity Ratio | 0.43 |
| Earnings Per Share (EPS) | ₹6.67 |
| Net Asset Value (NAV) Per Share | ₹62.76 |
| Price to Earnings (P/E) | 51.57x – 54.26x |
These indicators should be interpreted alongside the company’s business model and financial statements. Valuation ratios, including price-to-earnings, require a confirmed issue price and an appropriate earnings figure. Investors should avoid comparing ratios calculated on different reporting bases.
Objects of the Sahajanand Medical Technologies IPO
The proposed IPO has been described as an Offer for Sale by existing shareholders. In an OFS, existing shareholders sell their equity shares to public investors, and the proceeds are received by those selling shareholders rather than by the company.
- Offer for Sale – Existing shareholders propose to sell a specified number of equity shares under the public issue.
- Proceeds to Selling Shareholders – The money received from the sale of shares will be paid to the relevant selling shareholders.
- Proceeds to the Company – An OFS does not directly raise fresh capital for the company. The final RHP should be checked for confirmation of the final issue structure and any changes to the offer.
Investors should examine the final offer documents for the selling shareholders, the number of shares offered by each, and the proportion of their holdings being sold. The offer structure is important when assessing the purpose of the IPO and the company’s post-issue shareholding.
Sahajanand Medical Technologies IPO Listing Performance
Listing performance measures how a company’s shares trade when they begin trading on the stock exchanges. The listing price and initial return depend on the issue price and the market price at listing. As the final price band and listing details are not confirmed in the information cited here, listing gains cannot be calculated reliably.
| Particular | Value |
|---|---|
| Listing Exchange | BSE & NSE |
| Listing Date | 23 October 2026 |
| Issue Price | ₹344.00 (Upper Band) |
| Listing Price | To be updated after listing |
| Listing Gain | To be updated after listing |
| Listing Gain (%) | To be updated after listing |
The listing performance figures should be updated after the shares commence trading. Investors should distinguish short-term listing movements from the company’s longer-term business and financial performance.
Sahajanand Medical Technologies IPO Subscription Status
Subscription figures show investor participation during the IPO bidding period. They indicate the demand received from institutional, non-institutional, and retail investors. Subscription information should be updated using the latest exchange data once bidding begins.
Sahajanand Medical Technologies IPO Subscription
| Investor Category | Subscription |
|---|---|
| Qualified Institutional Buyers (QIB) | To be updated |
| Non-Institutional Investors (NII) | To be updated |
| Retail Individual Investors (RII) | To be updated |
| Employee Category | To be updated, if applicable |
| Total Subscription | To be updated |
The final subscription figures will reflect applications received across the eligible investor categories. Subscription levels are only one factor to consider and do not guarantee listing gains or future investment returns.
Sahajanand Medical Technologies IPO Review
Sahajanand Medical Technologies Limited operates in the specialised medical devices industry, focusing on cardiovascular and vascular intervention products. Its product portfolio includes drug-eluting stents, coronary balloons, structural heart products, occluders, and other specialised devices. The company’s manufacturing presence in India and Thailand and its international business operations are relevant factors when assessing its market reach.
A key consideration for investors is the company’s position in a technically demanding industry. Medical device manufacturers must maintain product quality, comply with regulatory requirements, and demonstrate the clinical performance of their products. Product development and successful commercialisation can support business growth, but these activities also involve investment and execution risks.
The company’s financial performance has improved in the reported period. Total income increased from ₹908.59 crore in FY2024 to ₹1,035.96 crore in FY2025 and ₹1,218.73 crore in FY2026. Profit after tax moved from a loss in FY2024 to positive earnings in FY2025 and FY2026. Investors should also consider the increase in borrowings, cash flow, working capital, operating expenses, and the sustainability of the reported earnings.
The proposed Offer for Sale structure is another important consideration. Under this structure, proceeds from the sale of shares are received by the selling shareholders rather than directly by the company. Investors should examine the selling shareholders, the quantity of shares being offered, and the post-issue ownership structure disclosed in the final offer documents.
The company also faces risks associated with medical device regulation, product quality, competition, technological changes, research and development, and international operations. A final investment assessment should consider these risks alongside the company’s financial performance and issue valuation.
Overall, Sahajanand Medical Technologies IPO merits careful evaluation based on its product portfolio, financial results, competitive position, final offer structure, and valuation. Investors should read the final RHP and assess whether the issue is appropriate for their individual investment objectives and risk tolerance.
Sahajanand Medical Technologies IPO Strengths
- Specialised Product Portfolio – The company operates in cardiovascular and vascular intervention medical devices, a specialised segment of healthcare.
- Diverse Medical Devices – Its products include coronary stents, coronary balloons, structural heart products, occluders, and peripheral intervention devices.
- International Presence – The company has operations and product distribution across domestic and overseas markets.
- Manufacturing Capabilities – Manufacturing operations in India and Thailand support its production and supply network.
- Financial Improvement – Reported income and profit after tax increased over the FY2024–FY2026 period.
- Research and Development – Medical device innovation and product development are important elements of the company’s business model.
- Exposure to Specialised Healthcare Demand – Cardiovascular intervention products serve an important area of medical treatment.
These potential strengths should be considered alongside the company’s regulatory obligations, competitive environment, financial position, and IPO valuation.
Sahajanand Medical Technologies IPO Risk Factors
- Regulatory Compliance – Medical devices must comply with applicable safety, quality, and approval requirements in each market.
- Product Quality and Safety – Product defects, recalls, or clinical performance issues could affect reputation and operations.
- Competition – The company competes with domestic and international manufacturers of cardiovascular and other medical devices.
- Research and Development Risk – Product development requires investment and does not guarantee successful commercialisation.
- International Business Risk – Overseas operations can be affected by currency movements, local regulation, distribution costs, and market conditions.
- Manufacturing Risk – Production depends on quality control, reliable suppliers, operational efficiency, and consistent product standards.
- Borrowings and Financial Risk – Investors should review the company’s borrowings, interest costs, working capital, and cash flows.
- Offer for Sale Structure – Proceeds from the sale of existing shares go to selling shareholders rather than directly funding the company’s business.
- Valuation Risk – The investment case depends partly on the final issue price relative to earnings, assets, growth, and comparable companies.
Investors should read the complete risk-factor section of the final RHP before making an investment decision.
Sahajanand Medical Technologies IPO Promoters
Sahajanand Medical Technologies Limited identifies Bhargav Dhirajlal Kotadia, Dhirajlal Vallabhbhai Kotadia, Priyanka Dhirajlal Cohen, and Shree Hari Trust among its promoters in the IPO information available from the company’s offer documentation.
Sahajanand Medical Technologies IPO Promoters Details
| Promoter | Designation |
|---|---|
| Bhargav Dhirajlal Kotadia | Promoter |
| Dhirajlal Vallabhbhai Kotadia | Promoter |
| Priyanka Dhirajlal Cohen | Promoter |
| Shree Hari Trust | Promoter |
The promoter shareholding before and after the offer, together with the shares being sold by each selling shareholder, should be checked in the final RHP.
Sahajanand Medical Technologies IPO Management Team
The company’s management is responsible for overseeing strategy, financial performance, manufacturing, product development, regulatory compliance, and business operations. The final RHP should be consulted to verify the full list of directors and key managerial personnel at the time of the IPO.
| Name | Designation |
|---|---|
| Bhargav Kotadia | Managing Director & Chief Executive Officer |
| Amit Khandelia | Chief Financial Officer |
| Deepshikha Singhal | Company Secretary & Compliance Officer |
The company’s official investor contact page identifies Bhargav Kotadia as Managing Director and Chief Executive Officer, Amit Khandelia as Chief Financial Officer, and Deepshikha Singhal as Company Secretary and Compliance Officer. Confirm these details against the final IPO documents before publication.
Sahajanand Medical Technologies IPO Registrar Details
The registrar manages application processing, the basis of allotment, refunds, share credit to demat accounts, and investor queries related to the public issue. The registrar for this IPO should be identified from the final RHP or official issue announcement.
| Particular | Details |
|---|---|
| Registrar Name | MUFG Intime India Private Limited |
| Website | https://in.mpms.mufg.com |
| IPO Allotment Status | https://in.mpms.mufg.com/Initial_Offer/public-issues.html |
| Email ID | [email protected] |
| Contact Number | +91 22 4918 6000 |
Investors should use only the registrar and allotment links officially announced for the Sahajanand Medical Technologies IPO. Do not enter PAN or demat details on unofficial websites.
Sahajanand Medical Technologies IPO Lead Manager Details
The Book Running Lead Managers coordinate the public issue, assist with regulatory and exchange procedures, manage the book-building process, and support the issuer during the IPO.
| Particular | Details |
|---|---|
| Lead Managers | Motilal Oswal Investment Advisors Limited, Avendus Capital Private Limited, HSBC Securities & Capital Markets (India) Private Limited, and Nuvama Wealth Management Limited |
The final lead manager names should be copied from the final offer documents to ensure that the published information reflects the confirmed issue arrangements.
Sahajanand Medical Technologies Limited Contact Details
| Particular | Details |
|---|---|
| Company Name | Sahajanand Medical Technologies Limited |
| Registered Office | Sahajanand Estate, Wakhariawadi, Near Dabholi, Ved Road, Surat, Gujarat – 395004, India |
| Corporate Office | Unit No. 402 & 412, A-Wing, 4th Floor, Kanakia Wall Street, Andheri-Kurla Road, Chakala, Andheri East, Mumbai, Maharashtra – 400093, India |
| Website | https://www.smtpl.com |
| Email ID | [email protected] |
| Contact Number | +91 22 4956 4000 |
The above contact information is available through the company’s official website and investor contact information.
How to Check Sahajanand Medical Technologies IPO Allotment Status
Investors can check the IPO allotment status after the basis of allotment has been finalised. The registrar’s website and the BSE IPO portal are the preferred channels for checking application results once the issue-specific allotment links are available.
Through MUFG Intime India Private Limited
- Visit the official MUFG Intime IPO allotment portal.
- Select Sahajanand Medical Technologies IPO from the list of public issues, when available.
- Choose the identification option provided, such as PAN, application number, or DP/Client ID.
- Enter the required details accurately.
- Submit the information to view the allotment status.
Through BSE
- Visit the official BSE website and navigate to the IPO allotment status service.
- Select Sahajanand Medical Technologies IPO from the available issue list.
- Enter your PAN or application details as requested.
- Complete any verification process displayed on the portal.
- Submit the information to check the allotment result.
The IPO-specific links should be used only after the registrar and exchange publish the relevant details. Investors should avoid unofficial allotment websites that request unnecessary personal or financial information.
Sahajanand Medical Technologies IPO Conclusion
Sahajanand Medical Technologies IPO provides an opportunity for investors to evaluate a company operating in specialised cardiovascular and vascular intervention medical devices. Its product portfolio includes coronary stents, coronary balloons, structural heart devices, occluders, and other medical products. Its manufacturing operations in India and Thailand and its international business provide exposure to multiple healthcare markets.
The company’s reported financial performance shows an improvement in income and profitability over FY2024–FY2026. However, investors should also assess borrowings, cash flow, operating expenses, competitive pressures, regulatory requirements, and the sustainability of earnings. The final issue valuation is an important consideration when determining whether the proposed offering represents an appropriate investment opportunity.
The proposed Offer for Sale structure means the proceeds from the sale of existing shares go to the selling shareholders rather than directly to the company. Investors should therefore examine the final shareholding structure, offer size, selling shareholder disclosures, and other details in the final prospectus.
A careful assessment of the company’s financial performance, product portfolio, business strategy, competitive strengths, risk factors, and valuation can help investors decide whether the IPO fits their investment objectives. The final decision should be based on official offer documents and individual risk tolerance rather than expected listing gains alone.
Sahajanand Medical Technologies IPO FAQs
What is Sahajanand Medical Technologies IPO?
Sahajanand Medical Technologies IPO is the proposed Mainboard public issue of Sahajanand Medical Technologies Limited, an Indian medical technology company specialising in cardiovascular and vascular intervention products.
What is the price band of Sahajanand Medical Technologies IPO?
The final price band has not been confirmed in the sources checked for this page. It should be updated after the official price-band announcement.
What is the issue size of Sahajanand Medical Technologies IPO?
The final issue size should be confirmed from the latest RHP and official issue announcement. IPO Watch reports an Offer for Sale of approximately 13,822,116 equity shares.
When will Sahajanand Medical Technologies IPO open?
The IPO is scheduled to open on 15 October 2026, according to currently published IPO information.
When will Sahajanand Medical Technologies IPO close?
The IPO is scheduled to close on 19 October 2026.
On which stock exchanges will Sahajanand Medical Technologies shares be listed?
The company’s equity shares are proposed to be listed on BSE and NSE, subject to the applicable approvals and completion of the IPO process.
Who is the registrar for Sahajanand Medical Technologies IPO?
MUFG Intime India Private Limited is identified as the registrar for the issue in currently available IPO information.
What is the face value of Sahajanand Medical Technologies IPO shares?
The face value of each equity share is ₹1.
What does Sahajanand Medical Technologies Limited do?
The company develops, manufactures, and markets specialised medical devices, including coronary stents, coronary balloons, structural heart products, occluders, and other vascular intervention devices.
What are the objects of Sahajanand Medical Technologies IPO?
The proposed offer has been described as an Offer for Sale by existing shareholders. Under this structure, the proceeds from the sale of offered shares are received by the selling shareholders rather than directly by the company.
What is the allotment date of Sahajanand Medical Technologies IPO?
The basis of allotment is currently reported for 21 October 2026. Investors should check the registrar’s website for the final confirmation.
What is the listing date of Sahajanand Medical Technologies IPO?
The tentative listing date is reported as 23 October 2026, subject to the final IPO schedule and stock exchange confirmation.
What is the lot size of Sahajanand Medical Technologies IPO?
The official lot size has not been confirmed in the sources checked for this page. It should be updated after the company announces the final price band and lot size.
How can I check Sahajanand Medical Technologies IPO allotment status?
Investors can check the allotment status through the official registrar’s website or the BSE IPO allotment service after the basis of allotment is finalised and the issue-specific links become available.
